1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Mucopolysaccharidosis Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Mucopolysaccharidosis Treatment Market Revenue and Volume, by Therapy Type
8.1.1 Enzyme Replacement Therapy
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Stem cell therapy (Bone marrow transplantation; Umbilical cord blood transplantation)
8.1.2.1. Market Revenue and Volume Forecast
9.1. Mucopolysaccharidosis Treatment Market Revenue and Volume, by Type of MPS
9.1.1. MPS I
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. MPS IV A
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. MPS II
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. MPS VI
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. MPS VII
9.1.5.1. Market Revenue and Volume Forecast
10.1. Mucopolysaccharidosis Treatment Market Revenue and Volume, by End User
10.1.1. Hospital
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Medical Research Centers
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Home-infusion
10.1.4.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Therapy Type
11.1.2. Market Revenue and Volume Forecast, by Type of MPS
11.1.3. Market Revenue and Volume Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Therapy Type
11.1.4.2. Market Revenue and Volume Forecast, by Type of MPS
11.1.4.3. Market Revenue and Volume Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Therapy Type
11.1.5.2. Market Revenue and Volume Forecast, by Type of MPS
11.1.5.3. Market Revenue and Volume Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Therapy Type
11.2.2. Market Revenue and Volume Forecast, by Type of MPS
11.2.3. Market Revenue and Volume Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Therapy Type
11.2.4.2. Market Revenue and Volume Forecast, by Type of MPS
11.2.4.3. Market Revenue and Volume Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Therapy Type
11.2.5.2. Market Revenue and Volume Forecast, by Type of MPS
11.2.5.3. Market Revenue and Volume Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Therapy Type
11.2.6.2. Market Revenue and Volume Forecast, by Type of MPS
11.2.6.3. Market Revenue and Volume Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Therapy Type
11.2.7.2. Market Revenue and Volume Forecast, by Type of MPS
11.2.7.3. Market Revenue and Volume Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Therapy Type
11.3.2. Market Revenue and Volume Forecast, by Type of MPS
11.3.3. Market Revenue and Volume Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Therapy Type
11.3.4.2. Market Revenue and Volume Forecast, by Type of MPS
11.3.4.3. Market Revenue and Volume Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Therapy Type
11.3.5.2. Market Revenue and Volume Forecast, by Type of MPS
11.3.5.3. Market Revenue and Volume Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Therapy Type
11.3.6.2. Market Revenue and Volume Forecast, by Type of MPS
11.3.6.3. Market Revenue and Volume Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Therapy Type
11.3.7.2. Market Revenue and Volume Forecast, by Type of MPS
11.3.7.3. Market Revenue and Volume Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Therapy Type
11.4.2. Market Revenue and Volume Forecast, by Type of MPS
11.4.3. Market Revenue and Volume Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Therapy Type
11.4.4.2. Market Revenue and Volume Forecast, by Type of MPS
11.4.4.3. Market Revenue and Volume Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Therapy Type
11.4.5.2. Market Revenue and Volume Forecast, by Type of MPS
11.4.5.3. Market Revenue and Volume Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Therapy Type
11.4.6.2. Market Revenue and Volume Forecast, by Type of MPS
11.4.6.3. Market Revenue and Volume Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Therapy Type
11.4.7.2. Market Revenue and Volume Forecast, by Type of MPS
11.4.7.3. Market Revenue and Volume Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Therapy Type
11.5.2. Market Revenue and Volume Forecast, by Type of MPS
11.5.3. Market Revenue and Volume Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Therapy Type
11.5.4.2. Market Revenue and Volume Forecast, by Type of MPS
11.5.4.3. Market Revenue and Volume Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Therapy Type
11.5.5.2. Market Revenue and Volume Forecast, by Type of MPS
11.5.5.3. Market Revenue and Volume Forecast, by End User
12.1. Immusoft Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Orchard Therapeutics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sarepta Therapeutics, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Abeona Therapeutics Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Denali Therapeutics Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Sangamo Therapeutics, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. REGENXBIO Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Sanofi (Sanofi Genzyme)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Ultragenyx Pharmaceutical Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. JCR Pharmaceuticals Co., Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
